التفاصيل البيبلوغرافية
| العنوان: |
Project T-SHARP: study protocol for a multi-site randomized controlled trial of tele-harm reduction for people with HIV who inject drugs |
| المؤلفون: |
Tookes, Hansel E., Oxner, Asa, Serota, David P., Alonso, Elizabeth, Metsch, Lisa R., Feaster, Daniel J., Ucha, Jessica, Suarez, Edward, Forrest, David W., McCollister, Kathryn, Rodriguez, Allan, Kolber, Michael A., Chueng, Teresa A., Zayas, Sheryl, McCoy, Bernice, Sutherland, Kyle, Archer, Chetwyn, Bartholomew, Tyler S. |
| المساهمون: |
National Institute on Drug Abuse |
| المصدر: |
Trials ; volume 24, issue 1 ; ISSN 1745-6215 |
| بيانات النشر: |
Springer Science and Business Media LLC |
| سنة النشر: |
2023 |
| مصطلحات موضوعية: |
Pharmacology (medical), Medicine (miscellaneous) |
| الوصف: |
Background The resurgence of HIV outbreaks and rising prevalence among people who inject drugs (PWID) remain exigent obstacles to Ending the HIV Epidemic in the USA. Adapting a low threshold, comprehensive treatment model for PWID with HIV can leverage syringe services programs (SSPs) to increase availability and accessibility of antiretrovirals (ART), medications for opioid use disorder (MOUD), and hepatitis C cure. We developed Tele-Harm Reduction , a telehealth-enhanced, harm reduction intervention delivered within an SSP venue. Methods The T-SHARP trial is an open-label, multi-site, randomized controlled superiority trial with two parallel treatment arms. Participants ( n =240) recruited from SSPs in Miami, Ft. Lauderdale, and Tampa, Florida, who are PWID with uncontrolled HIV (i.e., HIV RNA>200) will be randomized to Tele-Harm Reduction or off-site linkage to HIV care. The primary objective is to compare the efficacy of Tele-Harm Reduction for initiation of ART at SSPs vs. off-site linkage to an HIV clinic with respect to viral suppression across follow-up (suppression at 3, 6, and 12 months post randomization). Participants with HIV RNA<200 copies/ml will be considered virally suppressed. The primary trial outcome is time-averaged HIV viral suppression (HIV RNA <200 copies/ml) over 3-, 6-, and 12-month follow-up. Secondary outcomes include initiation of MOUD measured by urine drug screen and HCV cure, defined as achieving 12-week sustained virologic response (negative HCV RNA at 12 weeks post treatment completion). A cost-effectiveness analysis will be performed. Discussion The T-SHARP Trial will be the first to our knowledge to test the efficacy of an innovative telehealth intervention with PWID with uncontrolled HIV delivered via an SSP to support HIV viral suppression. Tele-Harm Reduction is further facilitated by a peer to support adherence and bridge the digital divide. This innovative, flipped healthcare model sets aside the traditional healthcare system, reduces multi-level ... |
| نوع الوثيقة: |
article in journal/newspaper |
| اللغة: |
English |
| DOI: |
10.1186/s13063-023-07074-w |
| DOI: |
10.1186/s13063-023-07074-w.pdf |
| DOI: |
10.1186/s13063-023-07074-w/fulltext.html |
| الإتاحة: |
https://doi.org/10.1186/s13063-023-07074-wTest |
| حقوق: |
https://creativecommons.org/licenses/by/4.0Test ; https://creativecommons.org/licenses/by/4.0Test |
| رقم الانضمام: |
edsbas.88187417 |
| قاعدة البيانات: |
BASE |
